It's stage III and contained.

In a new study, colon cancer patients on these medications were more likely to make it to the 5-year survival mark than patients not on the drugs. In a new study, colon cancer patients who took GLP-1 ...

Patients with colon cancer using GLP-1 receptor agonists (the class of drugs behind treatments like Ozempic, Wegovy, and Mounjaro) had substantially lower five-year death rates than those not using ...

New NCCN guidelines highlight how structured exercise and molecular profiling significantly reduce recurrence rates. Regular exercise is no longer just a recommendation for general health; it is now a ...

Gastroenterologists reveal the number-one sign of colon cancer. Plus, other symptoms to watch for and why the illness can be difficult to diagnose.

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. A three-year exercise program improved ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists—the class of drugs behind Ozempic, Wegovy and Mounjaro, for example—may ...

Colorectal cancer is increasing in young adults. Risk factors include age, metabolic syndrome, lifestyle choices, family ...

A short course of immunotherapy given before surgery eliminated detectable colon cancer in a majority of patients whose ...

Colon cancer is the leading cause of cancer deaths in people under the age of 50, according to the American Cancer Society, but what's behind the alarming surge and why are cases shifting? The issue ...